国立大学法人神戸大学;NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
发明人:
MATOZAKI, Takashi,的崎尚,MURATA, Yoji,村田陽二
申请号：
JPJP2017/023553
公开号：
WO2018/008470A1
申请日:
2017.06.27
申请国别(地区):
JP
年份:
2018
代理人:
摘要：
Provided is an SIRPα-targeting antitumor agent which inhibits the binding of CD47 to SIRPα and exerts an improved antitumor effect. Also provided is an antitumor agent which is capable of more effectively exerting an antitumor effect when used in combination with an immune check point inhibitor and/or an antibody medicine. The antitumor agent comprises as an active ingredient a substance the molecular target of which is the IgV domain that is an extracellular domain of SIRPα. The antitumor agent according to the present invention, said antitumor agent comprising as an active ingredient a substance the molecular target of which is the IgV domain of protein SIRPα, can activate M1-type cancer cytocidal macrophages and immune responsive cells and thus effectively exert an antitumor effect. When used in combination with an immune check point inhibitor and/or an antibody medicine capable of reacting specifically with a cancer antigen and having ADCC and ADCP activities, etc., moreover, the antitumor agent according to the present invention can effectively exert an antitumor effect not only on cancer cells expressing SIRPα on the cell surface but also on cancer cells not expressing the SIRPα.L'invention concerne un agent antitumoral ciblant le récepteur SIRPα, qui inhibe la liaison du CD47 à SIRPα et exerce un effet antitumoral amélioré. L'invention concerne également un agent antitumoral capable d'exercer plus efficacement un effet antitumoral lorsqu'il est utilisé en association avec un inhibiteur de point de contrôle immunitaire et/ou un médicament de type anticorps. L'agent antitumoral comprend comme principe actif une substance dont la cible moléculaire est le domaine IgV, un domaine extracellulaire de SIRPα. L'agent antitumoral de la présente invention, ledit agent antitumoral comprenant comme principe actif une substance dont la cible moléculaire est le domaine IgV de la protéine SIRPα, peut activer les macrophages de type M1 à activité cytotoxique contre le cancer
